Latest filing published 05 Sept 2024 for Athira Pharma, Inc..
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Rachel Lenington: trading record in brief
All filings by Rachel Lenington on record concern LeonaBio, Inc., in the capacity of senior executive. Between 22 June 2022 and 5 September 2024, the trades on record add up to 8 filings.
Sales make up the whole of the open-market record (4 sales, €25k). Other entries cover 4 share grants. In 2024 alone, the filings show no purchases and 3 sales.
The record was last updated on 5 September 2024 with an open-market sale (€1,286) in LeonaBio, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Rachel Lenington
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 10,000 shares0Common StockSEC:0001415889-24-022986:0
- 10,000 shares0Common StockSEC:0001415889-24-004155:0
- 10,000 shares0Common StockSEC:0001209191-24-001138:0
- 10,000 shares0Common StockSEC:0001209191-22-039338:0
4 of 4 declarations
